SEARCH

SEARCH BY CITATION

Cited in:

CrossRef

This article has been cited by:

  1. 1
    Paolo Pertile, Martin Forster, Davide La Torre, Optimal Bayesian sequential sampling rules for the economic evaluation of health technologies, Journal of the Royal Statistical Society: Series A (Statistics in Society), 2014, 177, 2
  2. 2
    Wenfeng Chen, Naiqing Zhao, Guoyou Qin, Jie Chen, A Bayesian Group Sequential Approach to Safety Signal Detection, Journal of Biopharmaceutical Statistics, 2013, 23, 1, 213

    CrossRef

  3. 3
    P. Brutti, F. De Santis, S. Gubbiotti, Robust Bayesian monitoring of sequential trials, METRON, 2013, 71, 1, 81

    CrossRef

  4. 4
    David Moher, Sally Hopewell, Kenneth F. Schulz, Victor Montori, Peter C. Gøtzsche, P.J. Devereaux, Diana Elbourne, Matthias Egger, Douglas G. Altman, CONSORT 2010 explanation and elaboration: Updated guidelines for reporting parallel group randomised trials, International Journal of Surgery, 2012, 10, 1, 28

    CrossRef

  5. 5
    Julia Varshavsky, Stacy Lindborg, Encyclopedia of Biopharmaceutical Statistics, Third Edition, 2012,

    CrossRef

  6. 6
    Weichung Shih, Encyclopedia of Biopharmaceutical Statistics, Third Edition, 2012,

    CrossRef

  7. 7
    Alice R. Pressman, Andrew L. Avins, Alan Hubbard, William A. Satariano, A comparison of two worlds: How does Bayes hold up to the status quo for the analysis of clinical trials?, Contemporary Clinical Trials, 2011, 32, 4, 561

    CrossRef

  8. 8
    Greg Ball, Linda B. Piller, Continuous safety monitoring for randomized controlled clinical trials with blinded treatment information, Contemporary Clinical Trials, 2011, 32, S5

    CrossRef

  9. 9
    Greg Ball, Michael H. Silverman, Continuous safety monitoring for randomized controlled clinical trials with blinded treatment information, Contemporary Clinical Trials, 2011, 32, S8

    CrossRef

  10. 10
    Julian P. T. Higgins, Anne Whitehead, Mark Simmonds, Sequential methods for random-effects meta-analysis, Statistics in Medicine, 2011, 30, 9
  11. 11
    David Moher, Sally Hopewell, Kenneth F. Schulz, Victor Montori, Peter C. Gøtzsche, P.J. Devereaux, Diana Elbourne, Matthias Egger, Douglas G. Altman, CONSORT 2010 Explanation and Elaboration: updated guidelines for reporting parallel group randomised trials, Journal of Clinical Epidemiology, 2010, 63, 8, e1

    CrossRef

  12. 12
    Weichung Joe Shih, Encyclopedia of Biopharmaceutical Statistics, 2010,

    CrossRef

  13. 13
    Julia A. Varshavsky, Stacy R. Lindborg, Encyclopedia of Biopharmaceutical Statistics, 2010,

    CrossRef

  14. 14
    Luke Akong’o Orawo, J. Andrés Christen, Bayesian sequential analysis for multiple-arm clinical trials, Statistics and Computing, 2009, 19, 1, 99

    CrossRef

  15. 15
    Steven Goodman, A Dirty Dozen: Twelve P-Value Misconceptions, Seminars in Hematology, 2008, 45, 3, 135

    CrossRef

  16. 16
    Xiao Zhang, Gary Cutter, Bayesian interim analysis in clinical trials, Contemporary Clinical Trials, 2008, 29, 5, 751

    CrossRef

  17. 17
    Steven Piantadosi, Jeanne Kowalski, Abeloff's Clinical Oncology, 2008,

    CrossRef

  18. 18
    Asher D. Schachter, Marco F. Ramoni, Gianluca Baio, Thomas G. Roberts, Stanley N. Finkelstein, Economic Evaluation of a Bayesian Model to Predict Late-Phase Success of New Chemical Entities, Value in Health, 2007, 10, 5
  19. You have free access to this content19
    Deborah Ashby, Bayesian statistics in medicine: a 25 year review, Statistics in Medicine, 2006, 25, 21
  20. 20
    Edward L. Korn, Boris Freidlin, The Likelihood as Statistical Evidence in Multiple Comparisons in Clinical Trials: No Free Lunch, Biometrical Journal, 2006, 48, 3
  21. 21
    Maria K. Mor, Stewart J. Anderson, A Bayesian Group Sequential Approach for Multiple Endpoints, Sequential Analysis, 2005, 24, 1, 45

    CrossRef

  22. 22
    Albert Cobos-Carbó, Ensayos clínicos aleatorizados (CONSORT), Medicina Clínica, 2005, 125, 21

    CrossRef

  23. 23
    Christopher H Schmid, Joseph C Cappelleri, Joseph Lau, Numerical Computer Methods, Part D, 2004,

    CrossRef

  24. 24
    Roger J. Lewis, Bayesian Modeling and Real-world Problems, Academic Emergency Medicine, 2003, 10, 7, 780

    CrossRef

  25. 25
    Weichung Shih, Encyclopedia of Biopharmaceutical Statistics, Second edition, 2003,

    CrossRef

  26. 26
    Donald J. Malec, Contrasting Bayesian analysis of survey data and clinical trials, Statistics in Medicine, 2001, 20, 9-10
  27. 27
    Hajime Uno, Shigeyuki Matsui, Nobuyuki Koyama, Bayesian Approaches to Interim Monitoring of Clinical Trials: A Review of Recent Theoretical Developments, Japanese Journal of Biometrics, 2000, 21, Special_Issue, S125

    CrossRef

  28. 28
    Shrikant I. Bangdiwala, Sergio R. Muñoz, Bioenvironmental and Public Health Statistics, 2000,

    CrossRef

  29. 29
    George D. Papandonatos, Seymour Geisser, Bayesian interim analysis of lifetime data, Canadian Journal of Statistics, 1999, 27, 2
  30. 30
    D. A. Berry, Benefits and Risks of Screening Mammography for Women in Their Forties: a Statistical Appraisal, JNCI Journal of the National Cancer Institute, 1998, 90, 19, 1431

    CrossRef

  31. 31
    Donald A. Berry, Stephen G. Eick, Adaptive assignment versus balanced randomization in clinical trials: A decision analysis, Statistics in Medicine, 1995, 14, 3
  32. 32
    Peter F. Thall, Richard M. Simon, Elihu H. Estey, Bayesian sequential monitoring designs for single-arm clinical trials with multiple outcomes, Statistics in Medicine, 1995, 14, 4
  33. 33
    Peter F. Thall, Richard Simon, A Bayesian approach to establishang sample size and monitoring criteria for phase II clinical trials, Controlled Clinical Trials, 1994, 15, 6, 463

    CrossRef

  34. 34
    Barry R. Davis, Robert J. Hardy, Data monitoring in clinical trials: The case for stochastic curtailment, Journal of Clinical Epidemiology, 1994, 47, 9, 1033

    CrossRef

  35. 35
    Roger J. Lewis, Donald A. Berry, Group Sequential Clinical Trials: A Classical Evaluation of Bayesian Decision-Theoretic Designs, Journal of the American Statistical Association, 1994, 89, 428, 1528

    CrossRef

  36. 36
    Ruth Etzioni, Margaret Sullivan Pepe, Monitoring of a pilot toxicity study with two adverse outcomes, Statistics in Medicine, 1994, 13, 22
  37. 37
    Peter F. Thall, Elihu H. Estey, A bayesian strategy for screening cancer treatments prior to phase ii clinical evaluation, Statistics in Medicine, 1993, 12, 13
  38. 38
    Roger J Lewis, Robert L Wears, An introduction to the Bayesian analysis of clinical trials, Annals of Emergency Medicine, 1993, 22, 8, 1328

    CrossRef

  39. 39
    John Whitehead, The case for frequentism in clinical trials, Statistics in Medicine, 1993, 12, 15-16
  40. 40
    Daniel F. Heitjan, Peter S. Houts, Harold A. Harvey, A decision-theoretic evaluation of early stopping rules, Statistics in Medicine, 1992, 11, 5
  41. You have full text access to this Open Access content41
    Steven Piantadosi, Nagahiro Saijo, Tomohide Tamura, Basic Design Considerations for Clinical Trials in Oncology, Cancer Science, 1992, 83, 6
  42. 42
    Richard Simon, A decade of progress in statistical methodology for clinical trials, Statistics in Medicine, 1991, 10, 12
  43. 43
    Donald A. Berry, Experimental design for drug development: a bayesian approach, Journal of Biopharmaceutical Statistics, 1991, 1, 1, 81

    CrossRef

  44. 44
    C. H. Ho, Some Frequentist Properties of a Bayesian Method in Clinical Trials, Biometrical Journal, 1991, 33, 6
  45. 45
    Stuart J. Pocock, Michael D. Hughes, Estimation issues in clinical trials and overviews, Statistics in Medicine, 1990, 9, 6
  46. 46
    James W. Vaupel, Relatives' risks: Frailty models of life history data, Theoretical Population Biology, 1990, 37, 1, 220

    CrossRef

  47. 47
    Barry R. Davis, Robert J. Hardy, Upper bounds for type I and type II error rates in conditional power calculations, Communications in Statistics - Theory and Methods, 1990, 19, 10, 3571

    CrossRef

  48. 48
    Gregory G. Enas, Bruce E. Dornseif, Charles B. Sampson, Frank W. Rockhold, Julie Wuu, Monitoring versus interim analysis of clinical trials: A perspective from the pharmaceutical industry, Controlled Clinical Trials, 1989, 10, 1, 57

    CrossRef

  49. 49
    Peter O'Brien, Statistical Methodology in the Pharmaceutical Sciences, 1989,

    CrossRef

  50. 50
    Donald Berry, Statistical Methodology in the Pharmaceutical Sciences, 1989,

    CrossRef

  51. 51
    Donald A. Berry, Interim Analyses in Clinical Research, Cancer Investigation, 1987, 5, 5, 469

    CrossRef

  52. 52
    Donald A. Berry, Interim Analysis in Clinical Trials: The Role of the Likelihood Principle, The American Statistician, 1987, 41, 2, 117

    CrossRef

  53. 53
    R.J. Brooks, On the design of comparative lifetime studies, Communications in Statistics - Theory and Methods, 1987, 16, 5, 1221

    CrossRef

  54. 54
    Curtis L. Meinert, Clinical Trials, Overview, Encyclopedia of Biostatistics,
  55. You have free access to this content55
    Curtis L. Meinert, Clinical Trials, Overview, Wiley StatsRef: Statistics Reference Online,
  56. 56
    Peter C. O'Brien, Data and Safety Monitoring, Encyclopedia of Biostatistics,
  57. 57
    Peter C. O'Brien, Data and Safety Monitoring, Wiley StatsRef: Statistics Reference Online,
  58. 58
    Anthony W. Fox, Phase II and Phase III Clinical Studies,